Healthcare utilization and unmet needs of patients with antisynthetase syndrome: An international patient survey

Abstract

Antisynthease syndrome (ASSD) is a rare, complex and understudied autoimmune disease. Internet-based studies can overcome barriers of traditional on-site research and are therefore very appealing for rare diseases. The aim of this study was to investigate patient-reported symptoms, diagnostic delay, symptoms, medical care, health status, working status, disease knowledge and willingness to participate in research of ASSD patients by conducting an international web-based survey. The multilingual questionnaire was created by an international group of rheumatologists and patients and distributed online. 236 participants from 22 countries completed the survey. 184/236 (78.0%) were female, mean age (SD) was 49.6 years (11.3) and most common antisynthetase antibody was Jo-1 (169/236, 71.6%). 79/236 (33.5%) reported to work full-time. Median diagnostic delay was one year. The most common symptom at disease onset was fatigue 159/236 (67.4%), followed by myalgia 130/236 (55.1%). The complete triad of myositis, arthritis and lung involvement verified by a clinician was present in 42/236 (17.8%) at disease onset and in 88/236 (37.3%) during the disease course. 36/236 (15.3%) reported to have been diagnosed with fibromyalgia and 40/236 (16.3%) with depression. The most reported immunosuppressive treatments were oral corticosteroids 179/236 (75.9%), followed by rituximab 85/236 (36.0%). 73/236 (30.9%) had received physiotherapy treatment. 71/236 (30.1%) reported to know useful online information sources related to ASSD. 223/236 (94.5%) were willing to share health data for research purposes once a year. Our results reiterate that internet-based research is invaluable for cooperating with patients to foster knowledge in rare diseases.

Dermatomyositis, Antisynthetase-Syndrom und immunvermittelte nekrotisierende Myopathie

“…Häufigkeit* bedacht werden [57,58] Die klassische Triade des Antisynthetase-Syndroms besteht aus Myositis, Polyarthritis und ILD [59], wobei sich die klinische Präsentation je nach vorliegendem Antikörperprofil unterscheiden kann [59,60]. Wichtig zu bedenken ist, dass die komplette Triade nur selten vorliegt (3-50 %) [59] und sich gerade zu Beginn nur einzelne Symptome zeigen können, was den/ die Kliniker:in vor Herausforderungen stellen kann.…”

“…Wichtig zu bedenken ist, dass die komplette Triade nur selten vorliegt (3-50 %) [59] und sich gerade zu Beginn nur einzelne Symptome zeigen können, was den/ die Kliniker:in vor Herausforderungen stellen kann. Entsprechend können teils lange Latenzen bis zur Diagnosestellung verzeichnet werden (im Schnitt 1 Jahr, jedoch werden bis zu 31 Jahre Latenz berichtet) [60].…”